These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 28703014

  • 21. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG®), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT).
    Solbeck S, Jensen AS, Maschmann C, Stensballe J, Ostrowski SR, Johansson PI.
    Scand J Clin Lab Invest; 2018; 78(1-2):25-30. PubMed ID: 29304563
    [Abstract] [Full Text] [Related]

  • 22. Dabigatran Use in the Real World: A Multihospital System Experience.
    Kimmons LA, Kabra R, Davis M, Segars BV, Oliphant CS.
    J Pharm Pract; 2014 Aug; 27(4):384-8. PubMed ID: 24319080
    [Abstract] [Full Text] [Related]

  • 23. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment.
    Bonello L, Laine M, Camoin-Jau L, Frere C.
    J Thromb Haemost; 2017 Jul; 15(7):1522-1523. PubMed ID: 28426920
    [No Abstract] [Full Text] [Related]

  • 24. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: reply.
    Achilles A, Mohring A, Zeus T, Kelm M, Polzin A.
    J Thromb Haemost; 2017 Jul; 15(7):1524-1525. PubMed ID: 28445598
    [No Abstract] [Full Text] [Related]

  • 25. Short-Term Cessation of Dabigatran Causes a Paradoxical Prothrombotic State.
    Kim J, Jang HJ, Schellingerhout D, Lee SK, Kim H, Kim YD, Lee KY, Choi HY, Cho HJ, Jang SS, Jeon S, Kwon IC, Kim K, Ryu WS, Nahrendorf M, Choi S, Kim DE.
    Ann Neurol; 2021 Mar; 89(3):444-458. PubMed ID: 33219556
    [Abstract] [Full Text] [Related]

  • 26. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT, Hu YF, Liao JN, Chern CM, Lin YJ, Chang SL, Wu CH, Sung SH, Wang KL, Lu TM, Chao TF, Lo LW, Hsu LC, Chung CP, Chang PM, Hsu WH, Chiou CW, Chen SA.
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [Abstract] [Full Text] [Related]

  • 27. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
    Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N.
    Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
    Honickel M, Maron B, van Ryn J, Braunschweig T, ten Cate H, Spronk HM, Rossaint R, Grottke O.
    Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
    [Abstract] [Full Text] [Related]

  • 33. Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran.
    Oi K, Shimizu M, Natori T, Tsuda K, Yoshida M, Kamada A, Ishigaku Y, Narumi S, Oura K, Maeda T, Terayama Y.
    Thromb Res; 2021 May; 201():123-130. PubMed ID: 33667955
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function.
    Martin JL, Esmaeili H, Manuel RC, Petrini M, Wiebe S, Maas H.
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):399-406. PubMed ID: 29695165
    [Abstract] [Full Text] [Related]

  • 35. Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience.
    Mumoli N, Mastroiacovo D, Tamborini-Permunian E, Vitale J, Giorgi-Pierfranceschi M, Cei M, Dentali F.
    J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):467-477. PubMed ID: 28509761
    [Abstract] [Full Text] [Related]

  • 36. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M.
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [Abstract] [Full Text] [Related]

  • 37. Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
    Blair HA, Keating GM.
    Drugs; 2017 Mar; 77(3):331-344. PubMed ID: 28185082
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.